AbbVie Downplays Impact Of Viekira Pak Safety Issues
This article was originally published in The Pink Sheet Daily
Because Child-Pugh B cirrhotic patients are such a small portion of hepatitis C population, AbbVie predicts labeling update won't make a material difference in sales; outreach to clinicians and health plans is going well, CEO Gonzalez adds.
You may also be interested in...
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.